Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Cell Depleted Alternative Donor Transplant for Severe Sickle Cell Disease and Transfusion-Dependent Anemias
NCT03653338Phase 2Recruiting
- Sponsor
- Paul Szabolcs
- Start
- Aug 2018
- Primary completion
- Aug 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD3/CD19 depleted hematopoietic stem cells in sickle cell anemia (SCA), beta thalassemia and Diamond-Blackfan anemia (DBA), sponsored by Paul Szabolcs. Primary endpoints: Graft rejection at 2 years, Post Transplant treatment related mortality at 1 year and 2 more. Started Aug 2018; status: recruiting.
02
Drugs
CD3/CD19 depleted hematopoietic stem cells
03
Conditions
sickle cell anemia (SCA)beta thalassemiaDiamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT03653338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653338.